Tag Archives: Bayer

India’s Generics-Big Pharma Battle Drops Drug Prices, Raises Legal Debate

Posted on May 21, 2012 by

Source: Intellectual Property Watch Patralekha Chatterjee 20 May 2012 The escalating battle between Big Pharma and India’s generic drug manufacturers is pushing down medicine prices in one of the world’s fastest growing pharmaceutical markets. German drug major Bayer AG is … Continue reading →

Posted in Compulsory Licensing, Indian Patent Law, TRIPS flexibilities | Tagged , , , | Leave a comment

Bayer seeks to stay the operation of the CL order – files appeal against the grant of the CL, before the IPAB in Chennai (India)

Posted on May 18, 2012 by

Acting on its press statement, German pharmaceutical company Bayer has filed an appeal against the Compulsory License (CL) order before the Intellectual Property Appellate Board (IPAB) in Chennai and has in particular sought to have the operation of the CL … Continue reading →

Posted in Compulsory Licensing, Indian Patent Law | Tagged , , , | Leave a comment

Compulsory licensing sets off a wave of price cuts in cancer drugs

Posted on May 10, 2012 by

Source: Livemint.com C.H. Unnikrishnan 8 May 2012 Mumbai: Prices of cancer medicines are dropping dramatically after India allowed Hyderabad’s Natco Pharma Ltd to sell a copy of German firm Bayer AG’s patented cancer drug Nexavar under compulsory licensing norms.   … Continue reading →

Posted in Compulsory Licensing, Indian Patent Law, TRIPS flexibilities | Tagged , , , , , | Leave a comment

Comments by Brook Baker: Bayer appeals against compulsory licence order

Posted on May 8, 2012 by

Source: Health GAP Professor Brook K. Baker 7 May 2012 Just as Novartis appealed from an order denying its patent application on Glivec, Bayer has now appealed the granting of a compulsory license on Nexavar,  Rather than honestly state that … Continue reading →

Posted in Compulsory Licensing, Indian Patent Law, R&D, TRIPS flexibilities | Tagged , | Leave a comment

Cipla slashes prices of anticancers in India

Posted on May 7, 2012 by

Source: Scrip Intelligence 03 May 2012, Anju Ghangurde Cipla has announced price cuts of about 60% or more across a clutch of oncology products, including its generic version of AstraZeneca’s lung cancer therapy, Iressa (gefitinib), in India. Cipla said that it … Continue reading →

Posted in Drug Pricing | Tagged , , , , , | Leave a comment

Bayer appeals against compulsory licence order

Posted on May 7, 2012 by

Source: Livemint C.H. Unnikrishnan, 5 May 2012 German drug maker Bayer HealthCare AG has appealed against the compulsory licence granted to Natco Pharma Ltd to manufacture and market cancer drug Nexavar by India’s Controller General of Patents. Bayer filed its … Continue reading →

Posted in Compulsory Licensing | Tagged , , , | Leave a comment

US to keep an eye on India’s compulsory drug licensing move

Posted on May 7, 2012 by

Source: Business Standard 06-May-2102 Puts India on priority watch list, which means US trade body doubts India over intellectual property rights The United States has taken a serious note of the developments that led India to issue the first compulsory … Continue reading →

Posted in Compulsory Licensing, data exclusivity, IPR Enforcement, TRIPS flexibilities, USTR 301 report | Tagged , , , | Leave a comment

‘The current patent system is deeply flawed’

Posted on May 2, 2012 by

Source: Frontline V. VENKATESAN 21 April 2012 Interview with Shamnad Basheer, Intellectual Property Law Professor at NUJS. SHAMNAD BASHEER: “Drug companies have been reluctant to disclose their costs of drug discovery and development to the public.” PROFESSOR Shamnad Basheer joined … Continue reading →

Posted in Compulsory Licensing, Indian Patent Law, IP Rights, Novartis Case, R&D, Sec 3 (d), TRIPS | Tagged , , | Leave a comment

Question of efficacy

Posted on May 2, 2012 by

Source: Frontline LEENA MENGHANEY 21 April 2012 The country is clearly shaping its legislation to promote access to medicines by fostering generic production.   INDIA’S approach to the revision of its Patents Act in 2005 is a clear example of … Continue reading →

Posted in access to medicines, Compulsory Licensing, Indian Patent Law, Novartis Case, patent evergreening, Sec 3 (d), TRIPS flexibilities | Tagged , , , , | Leave a comment

Western warnings

Posted on May 2, 2012 by

Source: Frontline R. RAMACHANDRAN 21 April 2012 India is coming under increasing pressure from the U.S. and the European Union for the strict patentability criteria it applies for medicines. RAJEEV BHATT Union Minister of Commerce and Industry Anand Sharma receives … Continue reading →

Posted in Compulsory Licensing, Indian Patent Law, Trans-Pacific Partnership Agreement, TRIPS flexibilities | Tagged , , , , | Leave a comment